BioLife Solutions, Inc. (NASDAQ:BLFS) CEO Greef Roderick De Sells 46,896 Shares

BioLife Solutions, Inc. (NASDAQ:BLFS) CEO Greef Roderick De sold 46,896 shares of the stock in a transaction dated Thursday, October 31st. The shares were sold at an average price of $23.43, for a total value of $1,098,773.28. Following the completion of the sale, the chief executive officer now owns 414,958 shares of the company’s stock, valued at approximately $9,722,465.94. This trade represents a 10.15 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

BioLife Solutions Stock Up 2.1 %

BLFS stock opened at $27.69 on Thursday. The stock has a market capitalization of $1.28 billion, a P/E ratio of -26.12 and a beta of 1.92. BioLife Solutions, Inc. has a 52 week low of $14.50 and a 52 week high of $28.88. The firm has a 50-day simple moving average of $25.91 and a 200-day simple moving average of $24.27. The company has a quick ratio of 1.78, a current ratio of 2.78 and a debt-to-equity ratio of 0.03.

Wall Street Analysts Forecast Growth

A number of research analysts have recently weighed in on the company. KeyCorp increased their price objective on BioLife Solutions from $30.00 to $33.00 and gave the company an “overweight” rating in a report on Friday, December 13th. Craig Hallum boosted their price objective on BioLife Solutions from $30.00 to $32.00 and gave the company a “buy” rating in a report on Wednesday, November 13th. Northland Securities raised their target price on BioLife Solutions from $28.00 to $31.00 and gave the stock an “outperform” rating in a report on Wednesday. HC Wainwright decreased their price target on BioLife Solutions from $29.00 to $27.00 and set a “buy” rating for the company in a report on Monday, November 18th. Finally, Benchmark reaffirmed a “buy” rating and set a $30.00 price objective on shares of BioLife Solutions in a research note on Thursday, December 19th. One research analyst has rated the stock with a sell rating and seven have given a buy rating to the stock. According to MarketBeat, BioLife Solutions has a consensus rating of “Moderate Buy” and an average target price of $29.43.

Hedge Funds Weigh In On BioLife Solutions

Several hedge funds and other institutional investors have recently made changes to their positions in the company. State Street Corp raised its stake in BioLife Solutions by 7.3% in the 3rd quarter. State Street Corp now owns 1,412,316 shares of the medical equipment provider’s stock valued at $35,364,000 after purchasing an additional 95,788 shares during the last quarter. Geode Capital Management LLC raised its position in shares of BioLife Solutions by 2.2% in the third quarter. Geode Capital Management LLC now owns 842,771 shares of the medical equipment provider’s stock valued at $21,107,000 after buying an additional 18,473 shares during the last quarter. The Manufacturers Life Insurance Company lifted its stake in shares of BioLife Solutions by 40.8% in the third quarter. The Manufacturers Life Insurance Company now owns 19,463 shares of the medical equipment provider’s stock worth $487,000 after buying an additional 5,638 shares in the last quarter. Barclays PLC grew its holdings in BioLife Solutions by 20.1% in the 3rd quarter. Barclays PLC now owns 64,423 shares of the medical equipment provider’s stock valued at $1,613,000 after buying an additional 10,803 shares in the last quarter. Finally, Mutual of America Capital Management LLC acquired a new stake in shares of BioLife Solutions in the 2nd quarter worth $8,592,000. Hedge funds and other institutional investors own 93.24% of the company’s stock.

About BioLife Solutions

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company’s products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.